Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 528 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... January 23, 2023 Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer May 21, 2024 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 Beauty, Healing and Space January 27, 2021 Load more HOT NEWS EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... Enfortumab Vedotin Approved for Recurrent Bladder Cancer 6 Things to Know About Regrowing and Caring for Your Hair... Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With...
